U.S. markets open in 4 hours 34 minutes
  • S&P Futures

    4,260.50
    +5.75 (+0.14%)
     
  • Dow Futures

    34,404.00
    +23.00 (+0.07%)
     
  • Nasdaq Futures

    14,143.25
    +18.50 (+0.13%)
     
  • Russell 2000 Futures

    2,324.10
    +0.50 (+0.02%)
     
  • Crude Oil

    70.96
    +0.08 (+0.11%)
     
  • Gold

    1,865.50
    -0.40 (-0.02%)
     
  • Silver

    27.77
    -0.26 (-0.94%)
     
  • EUR/USD

    1.2136
    +0.0013 (+0.11%)
     
  • 10-Yr Bond

    1.5010
    0.0000 (0.00%)
     
  • Vix

    16.38
    +0.73 (+4.66%)
     
  • GBP/USD

    1.4095
    -0.0013 (-0.09%)
     
  • USD/JPY

    110.1120
    +0.0510 (+0.05%)
     
  • BTC-USD

    39,812.14
    -495.84 (-1.23%)
     
  • CMC Crypto 200

    999.82
    +30.98 (+3.20%)
     
  • FTSE 100

    7,160.53
    +13.85 (+0.19%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 41st Annual Cowen Healthcare Conference on Tuesday, March 2, 2021, at 11:10 a.m. ET, and host investor meetings.

To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.

About Oyster Point Pharma, Inc.

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit. OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any use in any country. The safety and efficacy of OC-01 (varenicline) nasal spray have not previously been established.

Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com

Media Contact:
Sheryl Seapy
W2O Group
(213) 262-9390
sseapy@w2ogroup.com